‘A F—ed-Up situation,’ Says MariMed CCO About How State Regulations Complicate Cannabis Edibles Strategy
What is the strategy for branding in a fragmented market? Was the topic Wednesday at the Benzinga Cannabis Capital…
EXCLUSIVE: Ric Flair Drip Cannabis Announces Expansion Into 6 New States
Ric Flair's cannabis brand, Ric Flair Drip Global, will expand to 6 new states in partnership with Cannabist Company Holdings Inc.
Canopy Growth CEO At Benzinga Conference: ‘I Don’t Think Our Investors Understand The Value That Sits Inside Of Canopy’
"I don't think we get any credit" for Wana, Jetty or Acreage, Canopy Growth CEO David Klein says.
Global Cannabis Strategies Post-German Legalization: Exclusive Insights From Curaleaf, Gold Flora, Verano
At the Benzinga Cannabis Capital Conference in Hollywood, Florida, Constantin von der Groeben, managing director of Demecan, declared…
Top Cannabis Diversification Secrets: Industry Leaders Reveal Strategies For Success At Benzinga Conference
Discover how cannabis leaders at the Benzinga Conference drive growth through diversification. Unveil the strategies for industry success.
EXCLUSIVE: CEO Of This California Company Has Advice On How To Beat The Illicit Cannabis Market, Shares His Formula At Benzinga Conference
Being locked up in prison for cannabis “has to end,” said Kyle Kazan, Glass House Brands Inc.‘s (CBOE…
EXCLUSIVE: Florida On Cusp Of Adult-Use Legalization Cannabis Sales Boom, CEO Tells Benzinga Conference — ‘It’s Going To Be Huge’
'Florida has a million medical card holders, 23 million people living in the state, 130 million visitors a year — it's going to be huge,' says AYR Wellness CEO David Goubert.
Ultragenyx Announces Update To Conference Call Timing To Discuss New Data From GTX-102 In Patients With Angelman Syndrome; Conference Call Now Scheduled For Monday, April 15 At 8:00 a.m. ET
Conference call now scheduled for Monday, April 15 at 8:00 a.m. ET Updated registration link belowNOVATO, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced that
EXCLUSIVE: Lithium Market Faces ‘Daunting’ Supply-Demand Challenge, Says Nevada Lithium CEO
"I have never seen a mismatch in supply and demand in my 30 years of experience following commodities," Stephen Rentschler says.
Molecular Templates Presents Interim Data From MT-6402 Phase I Study In Patients With PD-L1+ Solid Tumors At 2024 AACR Annual Meeting
The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:MT-6402 has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed MT-6402 acts uniquely